Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.

Crespo-Facorro B, Pérez-Iglesias R, Mata I, Caseiro O, Martínez-Garcia O, Pardo G, Ramirez-Bonilla M, Pelayo-Terán JM, Vázquez-Barquero JL.

J Psychiatr Res. 2011 Jun;45(6):763-9. doi: 10.1016/j.jpsychires.2010.11.002. Epub 2010 Nov 23.

PMID:
21106207
2.

Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.

Crespo-Facorro B, Pérez-Iglesias R, Mata I, Ramirez-Bonilla M, Martínez-Garcia O, Pardo-Garcia G, Caseiro O, Pelayo-Terán JM, Vázquez-Barquero JL.

J Psychopharmacol. 2011 Jun;25(6):744-54. doi: 10.1177/0269881110388332. Epub 2011 Feb 3.

PMID:
21292922
3.

Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.

Crespo-Facorro B, Rodríguez-Sánchez JM, Pérez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, Martínez-Garcia O, Vázquez-Barquero JL.

J Clin Psychiatry. 2009 Apr 21;70(5):717-29. doi: 10.4088/JCP.08m04634.

PMID:
19389335
4.

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J.

J Clin Psychiatry. 2006 Oct;67(10):1511-21.

PMID:
17107241
5.

Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Ortiz V, Pelayo-Terán JM, Valdizan E, Vazquez-Barquero JL.

Psychopharmacology (Berl). 2012 Jan;219(1):225-33. doi: 10.1007/s00213-011-2392-3. Epub 2011 Jul 7.

PMID:
21735072
6.

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL.

J Clin Psychiatry. 2007 Nov;68(11):1733-40.

PMID:
18052567
7.

Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.

Ayesa-Arriola R, Rodríguez-Sánchez JM, Pérez-Iglesias R, Roiz-Santiáñez R, Martínez-García O, Sánchez-Moreno J, Tabarés-Seisdedos R, Vázquez-Barquero JL, Crespo-Facorro B.

Psychopharmacology (Berl). 2013 Jun;227(4):615-25. doi: 10.1007/s00213-013-2994-z. Epub 2013 Mar 2.

PMID:
23455591
8.

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

Dossenbach M, Arango-Dávila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assunção S.

J Clin Psychiatry. 2005 Aug;66(8):1021-30.

PMID:
16086618
9.

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.

Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G; Early Psychosis Global Working Group.

Am J Psychiatry. 2005 May;162(5):947-53.

PMID:
15863797
10.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
11.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
12.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
13.

Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.

Crespo-Facorro B, Roiz-Santiáñez R, Pérez-Iglesias R, Pelayo-Terán JM, Rodríguez-Sánchez JM, Tordesillas-Gutiérrez D, Ramírez M, Martínez O, Gutiérrez A, de Lucas EM, Vázquez-Barquero JL.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1936-43. doi: 10.1016/j.pnpbp.2008.09.020. Epub 2008 Oct 7.

PMID:
18930104
14.

One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.

San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E.

Psychiatry Res. 2012 Dec 30;200(2-3):693-701. doi: 10.1016/j.psychres.2012.07.005. Epub 2012 Sep 3.

PMID:
22954905
15.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group.

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
16.

A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.

Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA.

Neuropsychopharmacology. 2004 Jan;29(1):133-45.

17.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
18.

Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.

Shim JC, Choe BM, Kim JG, Jae YM, Kim HC, Kim SG, Oh MK, Kelly DL, Conley RR.

J Clin Psychopharmacol. 2007 Aug;27(4):400-1. No abstract available.

PMID:
17632229
19.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
20.

Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.

Díaz I, Pelayo-Terán JM, Pérez-Iglesias R, Mata I, Tabarés-Seisdedos R, Suárez-Pinilla P, Vázquez-Barquero JL, Crespo-Facorro B.

Psychiatry Res. 2013 Apr 30;206(2-3):181-7. doi: 10.1016/j.psychres.2012.10.011. Epub 2012 Nov 14.

PMID:
23159063

Supplemental Content

Support Center